Autor segons l'article: Masana, L; Plana, N; Andreychuk, N; Ibarretxe, D
Departament: Medicina i Cirurgia
Autor/s de la URV: Andreychuk Pasichna, Natalia / Ibarretxe Gerediaga, Daiana / Masana Marín, Luis / Plana Gil, Núria
Paraules clau: Statin Lipid-lowering therapy Inclisiran Icosapent ethyl High-risk patients Ezetimibe Evolocumab Combination therapy Cardiovascular prevention Bempedoic acid Atherosclerosis treatment Alirocumab statin society safety progression outcomes lipid-lowering therapy ldl-cholesterol inclisiran icosapent ethyl ezetimibe evolocumab efficacy coronary combination therapy cardiovascular events bempedoic acid atherosclerosis treatment alirocumab
Resum: Statins have contributed to the prevention of numerous atherosclerotic cardiovascular (CV) events and cardiovascular deaths in the past three decades. The benefit of statins is mainly mediated by the lowering of LDLc. According to scientific evidence, the current international guidelines recommend very low LDLc goals in patients at high/very high cardiovascular risk because they are associated with fewer CV events and improvements in atherosclerotic plaques. However, these goals often cannot be obtained with statins alone. Recent RCTs have demonstrated that these CV benefits can also be obtained with nonstatin LDLc-lowering drugs such as PCSK9 inhibitors (alirocumab and evolocumab), ezetimibe and bempedoic acid, while evidence with inclisiran is upcoming. Icosapent ethyl, a lipid metabolism modifier, has also shown an effect on event reduction. Physicians should take advantage of the currently available lipid-lowering therapies, choosing the drug or combination of drugs that is most appropriate for each patient according to his or her CV risk and baseline LDLc concentration. Strategies implementing combination therapies from early stages or even from the outset may increase the number of patients attaining LDLc goals, thereby preventing new CV episodes and improving existing atherosclerotic lesions.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Àrees temàtiques: Química Pharmacology & pharmacy Pharmacology Odontología Medicina ii Medicina i Interdisciplinar Farmacia Engenharias iv Engenharias ii Enfermagem Educação física Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciência de alimentos Biotecnología Biodiversidade Astronomia / física
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: daiana.ibarretxe@urv.cat luis.masana@urv.cat natalia.andreychuk@urv.cat
Identificador de l'autor: 0000-0002-0789-4954
Data d'alta del registre: 2024-08-03
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
Enllaç font original: https://www.sciencedirect.com/science/article/pii/S1043661823000944?via%3Dihub
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Pharmacological Research. 190 106738-106738
Referència de l'ítem segons les normes APA: Masana, L; Plana, N; Andreychuk, N; Ibarretxe, D (2023). Lipid lowering combination therapy: From prevention to atherosclerosis plaque treatment. Pharmacological Research, 190(), 106738-106738. DOI: 10.1016/j.phrs.2023.106738
DOI de l'article: 10.1016/j.phrs.2023.106738
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2023
Tipus de publicació: Journal Publications